pany & Its ProductsBloomberg Anywhere Remote LoginBloomberg

New Post Public Reply Private Reply Replies (0) Message Board
sambapati
417
pany & Its ProductsBloomberg Anywhere Remote LoginBloomberg Terminal Demo Request







Markets
Stocks
Currencies
Fixed Income
ETFs
Commodities
Rates + Bonds
Economics
Magazine
Benchmark
Watchlist
Economic Calendar
Tech
U.S.
Global
Startups
Bloomberg Technology TV
Gadgets With Gurman
Digital Defense
Studio 1.0
Focus On: Infrastructure
Deal of the Week: Over and Out
Magic Leap Raises $461 Million From Saudis
Apple's Fourth U.S. Campus: Handicapping Where It Will Go
CN Rail Abruptly Replaces CEO, Seeking to ‘Energize’ Company
Broadcom's $117 Billion Takeover Bid for Qualcomm Faces a New Hurdle
Pursuits
Cars & Bikes
Style & Grooming
Spend
Watches & Gadgets
Food & Drinks
Travel
Real Estate
Art & Design
Brilliant Ideas
Politics
Global Risk Briefing
All Signs Point to Big Democratic Wins in 2018
Trump Takes Credit for Killing Hundreds of Regulations That Were Already Dead
How China’s Top Leaders Came Into Power
How the Populist Right Is Redrawing the Map of Europe
Opinion
View
Gadfly
Businessweek
Latest Issue
Debrief Podcast
Subscribe
Sign In
Subscribe
RECOMMENDED VIEWING
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
2018-03-08T15:31:45Z Email
Facebook
Twitter
Google+
LinkedIn
Save
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders

PR Newswire

PETACH TIKVA, Israel, March 8, 2018

PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical
Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies
targeting a variety of different medical conditions and disorders, today
issued a chairman's statement to shareholders.

OWC Logo

In the light of recent events, and the numerous communications we have
received from shareholders, I would like to address this statement to the
Shareholders of OWCP (the "Company" .

The Company is committed to building a leadership position in the medical
cannabis market and to our mission of improving patients' lives through the
development of new solutions, products and devices derived from and delivery
mechanisms for the use of medical cannabis.

We have recruited a highly skilled management team with multi-year experience
in medical cannabis, pharmaceutical development, corporate management and
capital markets.

As we have stated in our 8-K filing of today, we are neither a party to the
pending SEC action against a former adviser to the Company, nor is the Company
alleged to have been a party to nor had any knowledge of the purported scheme
by the former adviser, who is the subject of the SEC action.

The Company's management is committed to and focused on our development
programs which are continuing as per plan. These include inter alia, our
current safety trial for our cannabis cream; the approval processes to
initiate a safety trial for our oral disintegrating tablet and additional
pipeline projects.

As a management team, we are committed to building value for our shareholders
though professional, ethical and strategic management of a technology platform
that we believe will bring improved health and quality of life to millions of
patients around the world. We have recently announced the addition of our new
Chief Scientific Officer and we continue to develop the resources we believe
will bolster our endeavors in creating a great company.

Yours sincerely,

Dr. Stanley Hirsch
Chairman of the Board

About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli
subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company'
conducts medical research and clinical trials to develop cannabis-based
pharmaceuticals and treatments for conditions including multiple myeloma,
psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique delivery systems for the effective delivery and
dosage of medical cannabis. All OWCP research is conducted at leading Israeli
hospitals and scientific institutions and led by internationally renowned
investigators. The Company's Research Division is focused on pursuing clinical
trials evaluating the effectiveness of cannabinoids and cannabis-based
products for the treatment of various medical conditions, while its Consulting
Division is dedicated to helping governments and companies navigate complex
international cannabis regulatory frameworks.

For more information visit: http://www.owcpharma.com/.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is
defined in Section 27A of the United States Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended. Statements
in this press release, which are not purely historical, are forward-looking
statements and include any statements regarding beliefs, plans, expectations
or intentions regarding the future. Such forward-looking statements include,
among other things, filing patent applications, product development, and
business strategy. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors include,
among others, the inherent uncertainties associated with new projects and
development stage companies. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements. Although we
believe that any beliefs, plans, expectations and intentions contained in this
press release are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate. Investors should
consult all of the information set forth herein and should also refer to the
risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB:
OWCP) periodic reports filed from time-to-time with the Securities and
Exchange Commission.

Contact Information::
Mordechai Bignitz , Chief Executive Officer – OWC Pharmaceutical Research
Corp.
Email: Mordechai.Bignitz@owcpharma.com
Tel: +972-(0)3-7582659



Cision View original
content:http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-issues-chairmans-statement-to-shareholders-300610781.html

SOURCE OWC Pharmaceutical Research Corp.

Website: http://www.owcpharma.com/

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Louis Pasteur -- chance favours only the prepared mind.
Lecture, University of Lille (7 December 1854)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading